http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110643034-B

Outgoing Links

Predicate Object
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G2650-04
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G65-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08G65-337
filingDate 2018-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2022-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2022-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-110643034-B
titleOfInvention Multi-arm PEG (polyethylene glycol) oritavancin derivative and preparation thereof
abstract The invention utilizes the characteristics of innocuity and easy combination of multi-arm PEG to respectively connect four-arm PEG, six-arm PEG and multi-arm PEG with oritavancin. The multi-arm PEG-loaded oritavancin prodrug has good water solubility, and the most important characteristic is that one multi-arm PEG chain can be connected with a plurality of oritavancin residues, so that the drug loading rate is greatly improved, and the half-life period of the drug is greatly prolonged, so that the existence time of the drug in plasma is remarkably prolonged, and the curative effect is improved.
priorityDate 2018-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018102890-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105849086-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008118784-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016046845-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6087
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419550086
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID12734
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID416014660
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419544653
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14969
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22174
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419524163
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7937
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419490115
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419491140
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507594
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419516651
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6228
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID422601301
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16136912
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14284
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID567658

Total number of triples: 41.